Trial Profile
Efficacy, Immunogenicity, and Safety Study of Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Clostridium difficile vaccine (Primary)
- Indications Clostridium difficile infections
- Focus Registrational; Therapeutic Use
- Acronyms Cdiffense
- Sponsors Sanofi Pasteur
- 03 Aug 2022 This trial has been completed in Denmark, according to European Clinical Trials Database record.
- 06 Feb 2019 This study has been completed in United Kingdom.
- 05 Feb 2018 Planned End Date changed from 1 Oct 2019 to 16 May 2019.